SL0439 / SenlangBio, Beijing GoBroad Hospital - LARVOL DELTA

SL0439: A structure-tuned bispecific nanobody CAR-T cells targeting BCMA/GPRC5D for relapsed/refractory multiple myeloma with extramedullary disease (ASH 2025) - P1 | "The BCMA/GPRC5D bispecific nanobody-based CAR-T (SL0349) has demonstrated superior structuralproperties and shows promising potential as a safe and effective therapeutic option for RRMM patients.Notably, it exhibits unique capabilities in eliminating EMDs and reducing the risk of antigen-negativerelapse post CAR-T infusion."

CAR T-Cell Therapy • IO biomarker • Acute Graft versus Host Disease • Acute Kidney Injury • Bone Marrow Transplantation • Gastroenterology • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Hepatology • Infectious Disease • Multiple Myeloma • Neutropenia • Renal Disease • Thrombocytopenia

Big Announcement | Senlang Biotechnology’s 6 Cutting-Edge Achievements to be Showcased at ASH2025 [Google translation] (Senlang Biotech Press Release) - "The company will officially release six of its latest clinical research findings during the conference, including its core products: CD7-targeted SENL101, CD19/BCMA dual-targeted SL1703, CD19/CD20 dual-targeted SL1716, and BCMA/GPRC5D dual-targeted SL0439."

Clinical data • Multiple Myeloma • Non-Hodgkin’s Lymphoma